• The overuse and misuse of antibiotics have led to the emergence of antibiotic-resistant bacteria, posing a significant threat to public health.
• Soligenix’s SGX943 is a novel broad-spectrum therapy designed to treat bacterial infections without relying on conventional antibiotics.
• Preclinical studies have demonstrated the efficacy of SGX943 in various models of bacterial infection.

In the face of escalating antibiotic resistance, the medical community is urgently seeking alternative treatments for bacterial infections. Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company, is at the forefront of this effort with its development of SGX943 (dusquetide), a novel broad-spectrum therapy designed to combat bacterial infections without relying on traditional antibiotics.

Antibiotics have been a cornerstone of modern medicine, effectively treating a wide range of bacterial infections. However, their overuse and misuse have led to the emergence of antibiotic-resistant bacteria, posing a significant threat to public health. According to the Centers for Disease Control and Prevention (“CDC”), at least 2.8 million people in the United States are infected with antibiotic-resistant bacteria annually, resulting in more than 35,000 deaths (https://ibn.fm/qjibe).

The challenge is compounded by the fact that antibiotics are often specific to certain types of bacteria, and their efficacy can be compromised by resistance mechanisms. Moreover, the development of new antibiotics has not kept pace with the rapid evolution of resistant strains, leaving clinicians with limited options for treatment. Globally, the World Health Organization (“WHO”) has identified antimicrobial resistance as one of the top ten public health threats facing humanity. The situation is dire: if left unaddressed, it is projected that antibiotic resistance could cause 10 million deaths per year by 2050, surpassing cancer as a leading cause of death (https://ibn.fm/vC6MQ).

It is within this context that alternative approaches to bacterial infection treatment have become critically important. Soligenix’s SGX943 represents one such approach that could change the paradigm. SGX943 is a novel broad-spectrum therapy designed to treat bacterial infections without relying on conventional antibiotics (https://ibn.fm/5RJFl). This promising therapy takes a fundamentally different approach by leveraging the body’s innate immune system rather than directly targeting pathogens, offering a powerful new tool in the fight against resistant bacterial infections.

Soligenix’s SGX943 therapy is based on dusquetide, an Innate Defense Regulator (“IDR”) that modulates the body’s immune response rather than directly targeting bacteria. By enhancing the innate immune system, SGX943 promotes the clearance of infections and reduces inflammation, offering a broad-spectrum approach to bacterial infections.

One of the key advantages of SGX943 is its ability to be effective regardless of the bacterial species involved. This means it can be administered before the specific pathogen is identified, providing a timely intervention in acute infections. Additionally, SGX943 can be used in conjunction with existing antibiotics, potentially enhancing their efficacy and mitigating the development of resistance.

Preclinical studies have demonstrated the efficacy of SGX943 in various models of bacterial infection, including those caused by antibiotic-resistant strains. Notably, the therapy has shown promise in treating melioidosis, a serious infection caused by Burkholderia pseudomallei, which is highly resistant to many antibiotics. The U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation to SGX943 for the treatment of melioidosis, recognizing its potential to address an unmet medical need.

The rise of antibiotic-resistant bacteria underscores the critical need for innovative therapies that go beyond traditional antibiotics. Soligenix’s SGX943 offers a novel approach by harnessing the body’s innate immune system to fight infections, providing a versatile and potentially more effective treatment option. As the medical community continues to grapple with the challenges of antibiotic resistance, therapies like SGX943 represent a hopeful advancement in the fight against bacterial infections.

Headquartered in Princeton, New Jersey, Soligenix operates within the medical, biomedical and genetics sector. The company’s portfolio encompasses both specialized biotherapeutics and public health solutions, targeting areas with significant unmet medical needs. Among its leading candidates are HyBryte(TM) (SGX301), a photodynamic therapy for cutaneous T-cell lymphoma (“CTCL”), and SGX942 (dusquetide), designed to address oral mucositis in patients undergoing chemoradiation for head and neck cancer.

For more information, visit www.Soligenix.com.

NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
[email protected]

MissionIR is powered by IBN